Paul Angulo1, David E Kleiner2, Sanne Dam-Larsen3, Leon A Adams4, Einar S Bjornsson5, Phunchai Charatcharoenwitthaya6, Peter R Mills7, Jill C Keach8, Heather D Lafferty7, Alisha Stahler8, Svanhildur Haflidadottir9, Flemming Bendtsen10. 1. Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center, Lexington, Kentucky. 2. Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland. Electronic address: kleinerd@mail.nih.gov. 3. Department of Medicine, Koege University Hospital, Koege, Denmark. 4. School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia. 5. Faculty of Medicine, University of Iceland, Section of Gastroenterology and Hepatology, National University Hospital, Reykjavik, Iceland. 6. Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 7. Gartnavel General Hospital, Glasgow, United Kingdom. 8. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 9. Department of Pediatrics, Rikshospitalet, Oslo University Hospital, Oslo, Norway. 10. Department of Gastroenterology, Hvidovre Hospital and Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND & AIMS: Histologic analysis of liver biopsy specimens allows for grading and staging of nonalcoholic fatty liver disease (NAFLD). We performed a longitudinal study to investigate the long-term prognostic relevance of histologic features for patients with NAFLD. METHODS: We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand. Patients underwent laboratory and biopsy analyses, and were examined every 3-12 months after their diagnosis. Outcomes analyzed were overall mortality, liver transplantation, and liver-related events. Cumulative outcomes were compared by log-rank analysis. Cox proportional-hazards regression was used to estimate adjusted hazard ratios (HRs). Time at risk was determined from the date of liver biopsy to the date of outcome or last follow-up examination. RESULTS: Over a median follow-up period of 12.6 years (range, 0.3-35.1 y), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% confidence interval [CI], 1.28-2.77), stage 2 (HR, 2.89; 95% CI, 1.93-4.33), stage 3 (HR, 3.76; 95% CI, 2.40-5.89), and stage 4 (HR, 10.9; 95% CI, 6.06-19.62) compared with stage 0, as well as age (HR, 1.07; 95% CI, 1.05-1.08), diabetes (HR, 1.61; 95% CI, 1.13-2.30), current smoking (HR, 2.62; 95% CI, 1.67-4.10), and statin use (HR, 0.32; 95% CI, 0.14-0.70). Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR, 14.2; 95% CI, 3.38-59.68) and stage 4 (HR, 51.5; 95% CI, 9.87-269.2) compared with stage 0, were associated significantly with the events. Patients with fibrosis, regardless of steatohepatitis or NAFLD activity score, had shorter survival times than patients without fibrosis. CONCLUSIONS: In a longitudinal study of patients with NAFLD, fibrosis stage, but no other histologic features of steatohepatitis, were associated independently with long-term overall mortality, liver transplantation, and liver-related events.
BACKGROUND & AIMS: Histologic analysis of liver biopsy specimens allows for grading and staging of nonalcoholic fatty liver disease (NAFLD). We performed a longitudinal study to investigate the long-term prognostic relevance of histologic features for patients with NAFLD. METHODS: We performed a retrospective analysis of 619 patients diagnosed with NAFLD from 1975 through 2005 at medical centers in the United States, Europe, and Thailand. Patients underwent laboratory and biopsy analyses, and were examined every 3-12 months after their diagnosis. Outcomes analyzed were overall mortality, liver transplantation, and liver-related events. Cumulative outcomes were compared by log-rank analysis. Cox proportional-hazards regression was used to estimate adjusted hazard ratios (HRs). Time at risk was determined from the date of liver biopsy to the date of outcome or last follow-up examination. RESULTS: Over a median follow-up period of 12.6 years (range, 0.3-35.1 y), 193 of the patients (33.2%) died or underwent liver transplantation. Features of liver biopsies significantly associated with death or liver transplantation included fibrosis stage 1 (HR, 1.88; 95% confidence interval [CI], 1.28-2.77), stage 2 (HR, 2.89; 95% CI, 1.93-4.33), stage 3 (HR, 3.76; 95% CI, 2.40-5.89), and stage 4 (HR, 10.9; 95% CI, 6.06-19.62) compared with stage 0, as well as age (HR, 1.07; 95% CI, 1.05-1.08), diabetes (HR, 1.61; 95% CI, 1.13-2.30), current smoking (HR, 2.62; 95% CI, 1.67-4.10), and statin use (HR, 0.32; 95% CI, 0.14-0.70). Twenty-six patients (4.2%) developed liver-related events; fibrosis stage 3 (HR, 14.2; 95% CI, 3.38-59.68) and stage 4 (HR, 51.5; 95% CI, 9.87-269.2) compared with stage 0, were associated significantly with the events. Patients with fibrosis, regardless of steatohepatitis or NAFLD activity score, had shorter survival times than patients without fibrosis. CONCLUSIONS: In a longitudinal study of patients with NAFLD, fibrosis stage, but no other histologic features of steatohepatitis, were associated independently with long-term overall mortality, liver transplantation, and liver-related events.
Authors: Elizabeth M Brunt; David E Kleiner; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Michael S Torbenson; Matthew Yeh Journal: Hepatology Date: 2011-07 Impact factor: 17.425
Authors: Emad A Rakha; Louise Adamson; Emily Bell; Keith Neal; Stephen D Ryder; Philip V Kaye; Guruprasad P Aithal Journal: J Clin Pathol Date: 2010-09 Impact factor: 3.411
Authors: Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck Journal: N Engl J Med Date: 2010-04-28 Impact factor: 91.245
Authors: Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri Journal: Hepatology Date: 2011-02-11 Impact factor: 17.425
Authors: Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri Journal: Hepatology Date: 2009-03 Impact factor: 17.425
Authors: Rohit Loomba; Nicholas Schork; Chi-Hua Chen; Ricki Bettencourt; Ana Bhatt; Brandon Ang; Phirum Nguyen; Carolyn Hernandez; Lisa Richards; Joanie Salotti; Steven Lin; Ekihiro Seki; Karen E Nelson; Claude B Sirlin; David Brenner Journal: Gastroenterology Date: 2015-08-20 Impact factor: 22.682
Authors: Robert J Pattison; James Phillip Esteban; Tomoki Sempokuya; Jakrin Kewcharoen; Sumodh Kalathil; Scott K Kuwada Journal: Hawaii J Health Soc Welf Date: 2020-06-01
Authors: Banrida Wahlang; Jian Jin; Juliane I Beier; Josiah E Hardesty; Erica F Daly; Regina D Schnegelberger; K Cameron Falkner; Russell A Prough; Irina A Kirpich; Matthew C Cave Journal: Curr Environ Health Rep Date: 2019-09
Authors: Yingzhen N Zhang; Kathryn J Fowler; Gavin Hamilton; Jennifer Y Cui; Ethan Z Sy; Michelle Balanay; Jonathan C Hooker; Nikolaus Szeverenyi; Claude B Sirlin Journal: Br J Radiol Date: 2018-06-06 Impact factor: 3.039